On October 28, 2016, Atomo Diagnostics received a $2.6 million grant from the Gates Foundation to develop a rapid HIV diagnostic kit that would help people in developing countries to test for rapid HIV infection. Amomo and the Foundation believe that by developing an affordable, reliable and simple HIV self-testing agent, HIV testing can be made easier for patients who cannot use existing medical basic testing services, especially those that require frequent testing. High risk patients. Atomo CEO John Kelly said in a statement that we have been working on a simple and affordable solution to avoid errors in the detection of existing HIV test kits. The Gates Foundation is very supportive of our company's development of this new and friendly testing method, which will also have a positive impact on global health. The funding of the Gates Foundation for us is a milestone for Atomo. Atomo will develop a rapid diagnostic reagent to meet the needs of national public health systems and individual users around the world at low and medium levels of development to detect HIV. This rapid diagnostic reagent can be used by researchers, healthcare professionals, and individual users. The company added that the company will work with public and private sectors in developing countries to promote the commercialization of this mysterious test reagent. Atomo is headquartered in Sydney, Australia, with offices in South Africa and the United Kingdom. In December 2013, Atomo released a professional test reagent for AtomoRapid HIV1&2, the world's first rapid HIV blood test reagent. In the second year of its launch, AtomoRapid won the highest award for Best Medical Design Award. This test reagent does not require a combination of multiple reagent components, making it easier, safer and more convenient to use. According to the news released by the WHO last month, based on the "90-90-90" treatment target, the demand for HIV rapid diagnostic reagents is expected to increase by 1/3, from 284 million in 2014 to 400 million in 2020. The "90-90-90" treatment goal is proposed in the UN/AIDS UN program, which means that by 2020: 90% of patients infected with HIV need to know the status of their HIV infection; 90% of patients diagnosed with HIV will receive continuous antiretroviral therapy; 90% of patients receiving continuous antiretroviral therapy will receive suppression of viral infection. Manual Breast Pump,Massage Breast Pump,Led Display Breast Pump,Manual Massage Breast Pump NINGBO YOUHE MOTHER&BABY PRODUCTS CO.,LTD , https://www.oembreastpump.com
HIV Rapid Diagnostic Reagent Receives 2.6 Million Funding from the Gates Foundation